🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This trial is investigating an intravenous (IV) medication called 9-ING-41 ...
Status
Active Not Recruiting
Location
Brigham and Women's Hospital
Start Date
2021-09-17
Trial ID
NCT05010629
Treatments Being Tested
The purpose of this study is to find out if an experimental drug will preve...
Status
Active Not Recruiting
Location
University of Colorado Cancer Center
Start Date
2022-03-21
Trial ID
NCT05077800
Treatments Being Tested
This is a study of the combination of 9 ING-41 (elraglusib) and retifanlima...
Status
Recruiting
Location
UPMC Hillman Cancer Center
Start Date
2025-09-22
Trial ID
NCT06896188
Treatments Being Tested
9-ING-41 is a small molecule potent selective GSK-3β inhibitor with antitum...
Status
Withdrawn
Location
Dana-Farber Cancer Institute
Start Date
2030-12-18
Trial ID
NCT04832438
Treatments Being Tested
This trial examines how Pancreatic Adenocarcinoma reacts to the addition of...
Status
Terminated
Location
Kansas University Cancer Center
Start Date
2022-01-26
Trial ID
NCT05239182
Treatments Being Tested
9-ING-41 has anti-cancer clinical activity while not causing myelosuppressi...
Status
Completed
Location
University of Southern California
Start Date
2020-08-20
Trial ID
NCT04218071
Treatments Being Tested
9-ING-41 in combination with gemcitabine and docetaxel will lead to sustain...
Status
Withdrawn
Location
Hasbro Children's Hospital
Start Date
2021-09
Trial ID
NCT04906876
Treatments Being Tested
This is an open label, two-stratum, phase 2 clinical trial evaluating the e...
Status
Withdrawn
Location
Hasbro Children's Hospital
Start Date
2022-03-01
Trial ID
NCT05116800
Treatments Being Tested
GSK-3β is a potentially important therapeutic target in human malignancies....
Status
Active Not Recruiting
Location
Mayo Clinic
Start Date
2019-01-04
Trial ID
NCT03678883
9-ING-41 has anti-cancer clinical activity with no significant toxicity in ...
Status
Terminated
Location
University of California, San Francisco
Start Date
2020-06-05
Trial ID
NCT04239092
Treatments Being Tested